DVAX (Dynavax Pharma) Earnings per share for the last twelve months

Public company logo of Dynavax Technologies (DVAX)

Automation of biological product production lines reduces personnel costs, as clearly demonstrated by the YoY TTM earnings per share trend for Dynavax Technologies (DVAX). The value of -310.10 determines the current status of the parameter. Dynavax Technologies (DVAX) revenues are based on the sale of the Heplisav-B vaccine through pharmacies and clinics. Meanwhile, patent protection and strict FDA regulations create a robust barrier for competitors, despite the risks associated with a narrow portfolio.

Dynavax (DVAX): Earnings per share for the last twelve months from 02/11/2024 to 02/21/2026

Financial and market metric breakdowns for Dynavax Technologies Corp (DVAX)

- market price and analyst price targets:
- business market valuation indicators:
Finished products of Dynavax Technologies Corporation

This indicator measures the trailing twelve-month (TTM) net income per share relative to the same period last year, eliminating the time lag associated with quarterly reporting. By analyzing the annual EPS growth rate over the last 12 months, investors assess the financial stability of Dynavax Technologies (DVAX), whose dominance in the hepatitis B vaccine segment confirms the business's ability to act as a stable cash generator.